Arcutis Biotherapeutics, Inc. ARQT Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s cumulative cost basis?
- Arcutis Biotherapeutics, Inc. (ARQT) reported cumulative cost basis of $189.48M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s cumulative cost basis changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s cumulative cost basis increased by 30.9% year-over-year, from $144.8M to $189.48M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s cumulative cost basis?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s cumulative cost basis has grown at a -4.1% compound annual growth rate (CAGR), from $219.36M to $177.96M.